1Sloan JA,McLeod H,Sargent D,et al.Preliminary evidence of relationship between genetic markers and oncology patient quality of life(QOL)[J].Proc Am Soc Clin Oncol,2004.
2Saltz LB, Niedzwiecki D, Hollis D, et al.Irinotecan plus fluorouracil/leucovorin(IFL) versus fluorouracil/leucovorin alone(FL) in stage Ⅲ colon cancer(intergroup trial CALGB C89803)[J].Proc Am Soc Clin Oncol,2004.
3Wolmark N,Wieand S,Lembersky B,et al.A phase Ⅲ trial comparing oral UFT to FULV in stage Ⅱ and Ⅲ carcinoma of the colon:Results of NSABP Protocol C-06[J].Proc Am Soc Clin Oncol,2004.
4Cassidy J,Scheithauer W,McKendrick J,et al.Capecitabine(X) vs bolus 5-FU/leucovorin(LV) as adjuvant therapy for colon cancer(the X-ACT study):efficacy results of a phase Ⅲ trial[J].Proc Am Soc Clin Oncol,2004.
5Cheverton P,Friess H,Andras C,et al.Phase Ⅲ results of exatecan(DX-8951f) versus gemcitabine(Gem) in chemotherapy-na?ve patients with advanced pancreatic cancer(APC)[J].Proc Am Soc Clin Oncol,2004.
6OReilly EM,Abou-Alfa GK,Letourneau R,et al.A randomized phase Ⅲ trial of DX-8951f(exatecan mesylate;DX) and gemcitabine(GEM) vs.gemcitabine alone in advanced pancreatic cancer(APC)[J].Proc Am Soc Clin Oncol,2004.
7Richards DA,Kindler HL,Oettle H,et al.A randomized phase Ⅲ study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer[J].Proc Am Soc Clin Oncol,2004.
8Louvet C,Labianca R,Hammel P,et al.GemOx(gemcitabine + oxaliplatin) versus Gem(gemcitabine) in non resectable pancreatic adenocarcinoma:Final results of the GERCOR /GISCAD Intergroup Phase Ⅲ[J].Proc Am Soc Clin Oncol,2004.
9Demetri GD,Desai J,Fletcher JA,et al.SU11248,a multi-targeted tyrosine kinase inhibitor,can overcome imatinib(IM) resistance caused by diverse genomic mechanisms in patients(pts) with metastatic gastrointestinal stromal tumor(GIST)[J].Proc Am Soc Clin Oncol,2004.
10Seidman AD,Berry D,Cirrincione C,et al.CALGB 9840:Phase Ⅲ study of weekly(W) paclitaxel(P) via 1-hour(h) infusion versus standard(S) 3h infusion every third week in the treatment of metastatic breast cancer(MBC),with trastuzumab(T) for HER2 positive MBC and randomized for T in HER2 normal MBC[J].Proc Am Soc Clin Oncol,2004.
